Abstract
Ocriplasmin is a recombinant protease approved as a nonsurgical treatment for vitreomacular traction (VMT) and small macular holes with vitreomacular adhesion (VMA). Successful ocriplasmin treatment in clinical studies has been defined as nonsurgical resolution of VMA as demonstrated on optical coherence tomography (OCT) by day 28 after intravitreal injection. This report presents three eyes with improvement in visual acuity and clinical symptoms despite only partial release of VMT over 28 days after ocriplasmin injection.
[Ophthalmic Surg Lasers Imaging Retina. 2015;46:271–274.]
- 1.Duker JS, Kaiser PK, Binder S, The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmol. 2013; 120(12):2611–2619.
10.1016/j.ophtha.2013.07.042 Crossref Medline, Google Scholar - 2.Stalmans P, Benz MS, Gandorfer A, Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes. N Engl J Med. 2012; 367(7):606–615.
10.1056/NEJMoa1110823 Crossref Medline, Google Scholar - 3.Bottós J, Elizalde J, Arevalo JF, Rodrigues EB, Maia M. Vitreomacular traction syndrome. J Ophthalmic Vis Res. 2012; 7(2):148–161. Medline, Google Scholar
- 4.Stalmans P, Girach A. Vitreous levels of active ocriplasmin following intravitreal injection: results of an ascending exposure trial. Invest Ophthalmol Vis Sci. 2013; 54(10):6620–6627.
10.1167/iovs.13-11811 Crossref Medline, Google Scholar
